Navigation Links
ChanTest Introduces the CardioChannelGram™ and SaVety Assessment

Cleveland, OH (PRWEB) April 16, 2013

Determining the drug-induced inhibition of the cardiac hERG potassium channel is recommended by both the International Conference on Harmonization (ICH) and the US Food and Drug Administration (FDA) in order to predict delayed cardiac repolarization (DR) and cardiac risk. However, extending this determination to actually identifying drugs that may cause TdP, a serious polymorphic ventricular tachycardia, has been challenging.

In response to this need, ChanTest has introduced the CardioChannelGram™ - cardiac ion channel profiling plus logistic regression models that predict DR and TdP risk. Predictivity is significantly better when quantitative drug effects on Cav1.2 and Nav1.5 ion channels, in addition to hERG, are measured. Cardiac risk can now be characterized earlier in development than ever before using automated patch clamp platforms.

“ChanTest is pleased to be responding to the industry's needs by introducing this new line of testing to the drug discovery community,” said Arthur "Buzz" Brown, Ph.D., M.D., CEO, President and founder. “Our new CardioChannelGram™ and SaVety Assessment will provide greater insight into potential cardiac risk, allowing more effective decision-making in early preclinical development.”

Click here to learn more about the ChanTest CardioChannelGram™ and SaVety Assessment.

14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.

Visit to learn more about what we do.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
2. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
3. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
4. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
5. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
6. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
7. Rigaku Introduces New Instruments at Pittcon 2013
8. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
9. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
10. Percival Scientific, Inc. Introduces an Affordable LED Lighting System for the Research Industry
11. Palomar Medical Center in San Diego County Introduces New Wrist-Worn Wireless Patient Vital Signs Device
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon ... over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... a wide range of applications such as, but not limited to, biotechnology, biomedical, ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
Breaking Biology Technology:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):